title: Commonly used drugs in hematologic disorders.
abstract: The drugs used to treat hematologic disorders constitute an extraordinary array of agents and include therapy for anemias, bleeding diatheses, thromboembolism and hematologic malignancies. Within many of these categories, hematologic therapies represent molecular understanding of the disease pathophysiology and a treatment targeted precisely at the known aberration. In this chapter we discuss these treatments, with greater emphasis on the most commonly used agents and the latest advances in the specific field. The chapter includes discussion on old (cyclooxygenase inhibitors) and new antiplatelet agents (ADP receptor P2Y12 inhibitors), newly described oral thrombin inhibitors such as dabigatran, treatment targeted at the bcr-abl tyrosine kinase in chronic myeloid leukemia and demethylating agents in myelodysplasia. The discussion is also oriented towards neurologic implications, both therapeutic and toxic, for each therapy or therapeutic group.
authors.affiliation: Division of Hematology and Oncology, Department of Medicine, Loyola University Chicago, Stritch School of Medicine, Maywood, IL, USA.
authors.forename: Elise
authors.initials: E
authors.lastname: Anderes
authors.affiliation: Division of Hematology and Oncology, Department of Medicine, Loyola University Chicago, Stritch School of Medicine, Maywood, IL, USA. Electronic address: snand@lumc.edu.
authors.forename: Sucha
authors.initials: S
authors.lastname: Nand
mesh_terms: D004791:Enzyme Inhibitors / Q000009:adverse effects*; D056947:Enzyme Replacement Therapy / Q000009:adverse effects; D006401:Hematologic Agents / Q000009:adverse effects*; D006402:Hematologic Diseases / Q000628:therapy*; D006801:Humans; D009422:Nervous System Diseases / Q000139:chemically induced*
chemical_list: D004791:Enzyme Inhibitors; D006401:Hematologic Agents
keywords: Iron; chemotherapy; cryoprecipitate; plasma; recombinant factors; tyrosine kinase inhibitors; vitamins